The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
The US Food and Drug Administration on Friday said it has approved Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years of age and older. 19 March 2022
Due to Russia’s military invasion of the Ukraine, global pharma companies are massively refusing to conduct clinical trials of their drugs in Russia, which means that the launch of these drugs in the local market will be impossible 19 March 2022
The British business of Japanese pharma major Takeda Pharmaceutical has secured conditional approval in the UK for its first-in-class oral tyrosine kinase inhibitor (TKI) Exkivity (mobocertinib). 18 March 2022
An Expert View from Jennifer Romanski, a principal of Porzio, Bromberg & Newman and a co-chair of its Life Sciences Compliance and Regulatory Counseling Department. She is also a senior vice president at Porzio Life Sciences, a wholly-owned subsidiary of the law firm. 18 March 2022
Rare diseases specialist Swedish Orphan Biovitrum, also known as Sobi, today announced that China’s National Medical Products Administration (NMPA) has approved Gamifant (emapalumab) for use in China. 18 March 2022
China’s Ignis Therapeutics and Germany’s STADA Arzneimittel’s Britannia Pharmaceuticals UK affiliate today jointly announced the signing of an exclusive licensing agreement under which Ignis Therapeutics will develop and commercialize subcutaneous apomorphine for Parkinson's disease in mainland China, Hong Kong and Macau. 18 March 2022
French drugmaker Sanofi has moved forward with the Euronext listing of EUROAPI, which has been billed as the future leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients (API). 18 March 2022
Chiesi Global Rare Diseases, a business unit of privately-held Italian drugmaker Chiesi Farmaceutici, and Israeli firm Protalix BioTherapeutics today announced final results from the Phase III BRIGHT study evaluating pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. 18 March 2022
Following the release of a draft text for the World Trade Organization (WTO)-led waiver on intellectual property (IP) for COVID-19 vaccines, the European Federation of Pharmaceutical Industries and Associations (EFPIA) calls on governments across Europe and around the world to urgently rethink discussions on a COVID vaccine waiver and instead focus on the real barriers to global vaccine equity. 18 March 2022
US mRNA specialist Moderna is the latest to request to the US Food and Drug Administration (FDA) for an amendment to the emergency use authorization (EUA) to allow for a fourth dose of its COVID-19 vaccine (mRNA-1273). 18 March 2022
The US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. 18 March 2022
In Germany and France, a new research collaboration will investigate the neurodegenerative disease spinocerebellar ataxia type 3 (SCA3), in collaboration with Servier Laboratories. 18 March 2022
The Medicines Patent Pool (MPP) has signed agreements with 35 companies to manufacture the generic version of Pfizer’s oral COVID-19 treatment Paxlovid (nirmatrelvir/ritonavir) to be supplied in 95 low- and middle-income countries. 17 March 2022
Shares of CNS focussed US pharma firm Impel NeuroPharma were up 5.3% at $6.98 early afternoon, having risen as high as $7.24, after it announced two separate transactions with funds managed by Oaktree Capital Management, totaling $100 million in gross funding. 17 March 2022
RNAi therapeutics company Alnylam Pharmaceuticals has begun patent infringement proceedings in respect of technologies used to develop two novel coronavirus vaccines. 17 March 2022
Boston, USA-based pricing watchdog The Institute for Clinical and Economic Review (ICER) has published a revised assessment of the relative merits of two possible competitors in hematology. 17 March 2022
France-based biotech OSE Immunotherapeutics’ shares closed up more than 5% at 7.54 euros yesterday, after it announced positive analysis of the long-term immune T cell responses of CoVepiT, its prophylactic vaccine candidate against COVID-19. 17 March 2022
Privately-held Danish dermatology specialist LEO Pharma today report financials for full-year 2021, noting that net sales grew 5% to 9,957 million kroner ($1.47 billion) when excluding discontinued and divested products. 17 March 2022
Swiss biopharma Relief Therapeutics’ subsidiary, APR Applied Pharma Research, has reported final data from its clinical trial of nasal spray, Sentinox, in SARS-CoV-2 infected patients. 17 March 2022